Project Grant HT94252410405
Award Date
9/1/24
Completion Date
8/31/27
Dollars Obligated
$1.4M
Federal Agency
Defense Health Agency
Awardee
Duke University (TP7EK8DZV6N5)
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Durham, NC 27705, USA
Similar Awards
The Department of Defense's Defense Health Agency awarded Duke University a $1,344,946 Project Grant on September 1, 2023 through the Military Medical Research and Development program (CFDA 12.420). This grant supports a 3-year research project titled "Understanding Heterogeneity and Improving the Precision of Prostate Cancer Clinical Outcomes in the Modern Era." The research aims to advance understanding and treatment of prostate cancer, with a focus on improving clinical outcomes for...
This $241,500 federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research at Duke University focused on "Understanding the Molecular Communication Between Prostate Cancer Cell Types". The award period runs from September 1, 2025 to August 31, 2027. As a leading research institution with expertise in medical research, Duke University will utilize this funding to conduct advanced scientific...
The Department of the Army Medical Command awarded Duke University a $2,139,404 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to support research on exploiting a new targetable node in the androgen receptor (AR) signaling pathway in prostate cancer. The three-year award runs from January 7, 2022 to June 30, 2025. Duke University will conduct research to transform healthcare for service members and the public through innovative and impactful medical...
The Department of the Army Medical Command awarded Duke University a $482,890 Project Grant under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from April 1, 2022 to March 31, 2024 to target the oncogenomic function of the E2F8 transcription factor in lethal prostate cancer. Through this funding, Duke University researchers will investigate medical solutions for prostate cancer at the genomic level, with the aim of transforming healthcare for...
The federal Project Grant award of $481,158.00 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) enables Duke University to conduct research aimed at "Blocking Glutamine Utilization in Advanced and Therapy-Resistant Prostate Cancer." The award supports a two-year project from June 1, 2024 to May 31, 2026 to expand the frontiers of scientific knowledge and apply it to address a critical medical challenge facing military service...
The Department of the Army Medical Command awarded Duke University a $472,184 Project Grant under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from September 1, 2022 to August 31, 2024 to exploit ferropotosis for the treatment of RB1-deficient lethal prostate cancer. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research with the goals of transforming military and public health care...
This Project Grant award from the Defense Health Agency provides $1,423,676 to Duke University from September 1, 2023 through August 31, 2026. The funding supports research targeting NUAK2 in neuroendocrine prostate cancer under the Military Medical Research and Development program (CFDA 12.420). The Military Medical Research and Development program aims to transform health care for service members and the public through innovative biomedical research. This award will further those goals by...
The Defense Health Agency awarded Duke University a $1,167,250 Project Grant (CFDA 12.420 - Military Medical Research and Development) with a performance period from June 1, 2024 to May 31, 2027. The grant funding supports Duke's research on the role of the NLRP3-NLRC5 signaling pathway in melanoma immune evasion and dormancy. The research aims to advance the understanding of mechanisms underlying melanoma progression, with the potential to inform new therapeutic approaches. As a prominent...
The Department of Defense's Defense Health Agency awarded a $4,818,759 Project Grant to Duke University under the Military Medical Research and Development program (CFDA 12.420) for the project "SINGLE-CELL AND SPATIAL ANALYSIS OF LETHAL BREAST CANCERS". The grant, awarded on April 1, 2024, will fund research to improve understanding and treatment of lethal breast cancers through advanced single-cell and spatial analysis techniques. This work supports the program's goals of...
Duke University was awarded a $931,969 project grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from July 1, 2023 to June 30, 2026 to develop epigenetic signatures to predict pathological nodal stage for de-escalation of axillary surgery in patients with clinically node-positive breast cancer. The research aims to transform patient care by investigating medical solutions that could help reduce the need...